Abstract:RAS oncogenes are master regulator genes in many cancers. In general, RAS -driven cancers have an oncogenic RAS mutation that promotes disease progression (colon, lung, pancreas). In contrast, brain tumors are not necessarily RAS -driven cancers because RAS mutations are rarely observed. In particular, glioblastomas (the most lethal brain tumor) do not appear to have dominant genetic mutations that are suitable for targeted therapy. Standard treatment for most brain tumors continues to focus on maximal surgical resection, radiotherapy and chemotherapy. Yet the convergence of genomic aberrations such as EGFR, PDGFR and NF1 (some of which are clinically effective) with activation of the RAS /MAPK cascade is still considered a key point in gliomagenesis, and KRAS is undoubtedly a driving gene in gliomagenesis in mice. In cancer, microRNAs (miRNA) are small, non-coding RNAs that regulate carcinogenesis. However, the functional consequences of aberrant miRNA expression in cancer are still poorly understood. let-7 encodes an intergenic miRNA that is classified as a tumour suppressor, at least in lung cancer. Let-7 suppresses a plethora of oncogenes such as RAS , HMGA, c-Myc, cyclin-D and thus suppresses cancer development, differentiation and progression. let-7 family members are direct regulators of certain RAS family genes by binding to the sequences in their 3′untranslated region (3′UTR). let-7 miRNA is involved in the malignant behaviour in vitro—proliferation, migration and invasion—of gliomas and stem-like glioma cells as well as in vivo models of glioblastoma multiforme (GBM) via KRAS inhibition. It also increases resistance to certain chemotherapeutic agents and radiotherapy in GBM. Although let-7 therapy is not yet established, this review updates the current state of knowledge on the contribution of miRNA let-7 in interaction with KRAS to the oncogenesis of brain tumours.

RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action

Microrna-148A-3p Inhibited the Proliferation and Epithelial-Mesenchymal Transition Progression of Non-Small-cell Lung Cancer Via Modulating Ras/MAPK/Erk Signaling

Function of Microrna-145 and Mechanisms Underlying Its Role in Malignant Tumor Diagnosis and Treatment

Epigenetic Silencing of a Ca2+-regulated Ras GTPase-activating Protein RASAL Defines a New Mechanism of Ras Activation in Human Cancers

RAS/MAPK Activation is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

The MAPK pathway across different malignancies: A new perspective

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

Oncogenic K-Ras suppresses global miRNA function

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications

The RAS oncogene in brain tumors and the involvement of let-7 microRNA

Synthesis and Regulation of miRNA, Its Role in Oncogenesis, and Its Association with Colorectal Cancer Progression, Diagnosis, and Prognosis

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

The prominent pervasive oncogenic role and tissue specific permissiveness of RAS gene mutations

miRNA on the Battlefield of Cancer: Significance in Cancer Stem Cells, WNT Pathway, and Treatment

The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer

Epigenetic Alterations of Tumor Marker Micrornas: Towards New Cancer Therapies.

Bridging Neuronal Dynamics and Cancer Pathogenesis through Mechanistic Target of Rapamycin Signaling

Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies